Health Economics & Market Access

AF Burden of Disease and Treatment

Health Economics & Market Access

AF Burden of Disease and Treatment

As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.

Atrial fibrillation is a chronic and typically progressive disease that significantly impairs patient quality of life and increases their risk of developing co-morbidities.2

AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3

AFib Burden of Disease Cover

Atrial Fibrillation Burden of Disease Report

The AFib Burden of Disease Report outlines the growing burden of AFib on patients, caregivers and healthcare systems across the United States, emphasizing the scale and impact of the disease.

AFib Treatment Report Cover

Atrial Fibrillation Management Report

The Atrial Fibrillation Management Report details current guideline-recommended treatment options for AFib as well as their long-term impact on clinical, patient and economic outcomes, aiming to support healthcare professionals (HCPs) when making treatment decisions.

1. Khavjou, Olga, D. Phelps, and A. Leib. “Projections of cardiovascular disease prevalence and costs: 2015–2035.” Dallas: American Heart Association (2016).
2. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al. (2016) Atrial _brillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta_ analysis. Bmj 354 i4482.
3. Boriani G, Proietti M (2017) Atrial _brillation prevention: an appraisal of current evidence. Heart

176134-210507